Monograph Details

Neoplasms > Hormones and antagonists
ZOLADEX
Manufacturer
AstraZeneca Pharmaceuticals
Legal Classification
Rx
Pharmacological Class
GnRH analogue.
Generic Name
Goserelin (as acetate) 3.6mg; SC implant.
Also
ZOLADEX 3-MONTH 10.8mg
Indications
Palliative treatment of advanced breast cancer in pre- and perimenopausal women. Palliative treatment of advanced prostate carcinoma. In combination with flutamide for management of locally confined Stage T2b-T4 (Stage B2-C) prostate carcinoma.
Children
Not applicable.
Adults
Implant SC into anterior abdominal wall. Breast cancer: one 3.6mg implant every 28 days. Prostate cancer: one 3.6mg implant every 28 days or one 10.8mg implant every 12 weeks. Stage B2-C prostatic carcinoma (in combination with flutamide): Treat 8 weeks prior to and during radiotherapy. Initially one 3.6mg implant, followed in 28 days by one 10.8mg implant; or may use one 3.6mg implant every 28 days.
Contraindications
Pregnancy (Cat.D). Nursing mothers.
Precautions
Nondiagnosed abnormal vaginal bleeding: not recommended. Risk factors for decreased bone mineral density (eg, chronic alcohol, tobacco, anticonvulsants, corticosteroids). Premenopausal women: use nonhormonal contraception during and for 12 weeks after therapy or until menses resume. Males: risk of ureteral obstruction or spinal cord compression (monitor during 1st month of therapy).
Interactions
May affect tests of pituitary-gonadotropic and gonadal functions.
Adverse Reactions
Females: hypoestrogenism (eg, hot flashes, headache, vaginal dryness, decreased libido, risk of decreased bone mineral density). Males: decreased testosterone levels (eg, hot flashes, sexual dysfunction, decreased erections, gynecomastia), lower urinary tract symptoms. Both: transient worsening of symptoms (eg, bone pain), tumor flare, GI upset, edema, malaise.
How Supplied
Implant (in syringe)—1
Additional Resources
Related Prescribing Note